Sanofi (SNY) Fly Vaccine Approved by FDA for 2022-2023 Influenza Season - StreetInsider.com

Today the US Food and Drug Administration (FDA) approved Sanofi's (NASDAQ: SNY) licensure request for vaccine approval for the upcoming 2022-2023 flu season, including: Fluzone High-Dose Quadrivalent (Influenza Vaccine), Flublok...

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premiumhere. Today the US Food and Drug Administration (FDA) approved Sanofi's (NASDAQ: S… [+2437 chars]

full article...